N
N van Baren
Researcher at Université catholique de Louvain
Publications - 7
Citations - 1275
N van Baren is an academic researcher from Université catholique de Louvain. The author has contributed to research in topics: Gene & Antigen. The author has an hindex of 6, co-authored 7 publications receiving 1205 citations. Previous affiliations of N van Baren include Ludwig Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
Marie Marchand,N van Baren,N van Baren,P. Weynants,P. Weynants,Vincent Brichard,Vincent Brichard,Vincent Brichard,Brigitte Dreno,M H Tessier,E Rankin,Giorgio Parmiani,Flavio Arienti,Yves Humblet,A Bourlond,Romain Vanwijck,Danielle Lienard,Marc Beauduin,Pierre-Yves Dietrich,Vincenzo Russo,Joseph Kerger,Giuseppe Masucci,Elke Jäger,J. P. De Greve,J Atzpodien,Francis Brasseur,Francis Brasseur,Pierre Coulie,P. van der Bruggen,P. van der Bruggen,Thierry Boon,Thierry Boon +31 more
TL;DR: The results suggest that injection of the MAGE‐3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.
Journal ArticleDOI
Genes encoding tumor-specific antigens are expressed in human myeloma cells
N van Baren,Francis Brasseur,Danièle Godelaine,Gérald Hames,Augustin Ferrant,Frederic Lehmann,Marc André,Christophe Ravoet,Chantal Doyen,Giulio C. Spagnoli,Marleen Bakkus,Kris Thielemans,Thierry Boon +12 more
TL;DR: A significant expression of genes of the MAGE, BAGE, GAGE, and LAGE-1/NY-ESO-1 families is detected in a high proportion of bone marrow samples from patients with advanced multiple myeloma, providing a basis for clinical trials aimed at inducing a cellular immune response directed at malignant plasma cells in advanced myel cancer patients.
Journal ArticleDOI
Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma
TL;DR: Indoleamine-2,3 dioxygenase 1 contributes to tumor immunosuppression by enzymatically degrading tryptophan, which is required for T cell activity, and producing kynurenine.
Journal ArticleDOI
Structure of the gene of tum- transplantation antigen P35B: presence of a point mutation in the antigenic allele.
Jean-Pierre Szikora,A Van Pel,Vincent Brichard,M. André,N van Baren,P. Henry,E De Plaen,Thierry Boon +7 more
TL;DR: Surprisingly, the homologous peptide corresponding to the normal sequence of the gene had the same effect, indicating that this tum‐ mutation does not exert its effect by generating the aggretope or the epitope of the antigenic peptide.
Journal ArticleDOI
MAGE-A genes are not expressed in human leukemias.
TL;DR: It is concluded that MAGE-A genes are not expressed in human leukemias after screening of a large panel including 154 patients, where only weak signal were detected in a few samples.